Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Tax Provisions: 2009-2024

Historic Tax Provisions for Amicus Therapeutics (FOLD) over the last 15 years, with Dec 2024 value amounting to $27.4 million.

  • Amicus Therapeutics' Tax Provisions rose 25.56% to $17.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.0 million, marking a year-over-year decrease of 47.59%. This contributed to the annual value of $27.4 million for FY2024, which is 1744.23% up from last year.
  • Latest data reveals that Amicus Therapeutics reported Tax Provisions of $27.4 million as of FY2024, which was up 1,744.23% from $1.5 million recorded in FY2023.
  • Over the past 5 years, Amicus Therapeutics' Tax Provisions peaked at $27.4 million during FY2024, and registered a low of -$5.5 million during FY2022.
  • For the 3-year period, Amicus Therapeutics' Tax Provisions averaged around $7.8 million, with its median value being $1.5 million (2023).
  • In the last 5 years, Amicus Therapeutics' Tax Provisions slumped by 161.43% in 2022 and then soared by 1,744.23% in 2024.
  • Over the past 5 years, Amicus Therapeutics' Tax Provisions (Yearly) stood at $2.6 million in 2020, then surged by 242.80% to $8.9 million in 2021, then tumbled by 161.43% to -$5.5 million in 2022, then soared by 127.11% to $1.5 million in 2023, then surged by 1,744.23% to $27.4 million in 2024.